Last $47.44 USD
Change Today +0.95 / 2.04%
Volume 1.4M
RMD On Other Exchanges
Symbol
Exchange
New York
OTC US
Frankfurt
Frankfurt
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

resmed inc (RMD) Key Developments

ResMed Mulls Partners

ResMed Inc. (NYSE:RMD) is seeking partners. ResMed is now looking for an electronics partner to work with to produce the devices, which will not require a prescription to buy, Mick Farrell, Chief Executive Officer of ResMed, said, The Australian Financial Review reported.

ResMed Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM

ResMed Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

ResMed Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 08:00 AM

ResMed Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 08:00 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States.

Apex Embarks on Counter Actions Against ResMed in Europe

Apex Medical Corporation announced at a press conference held on February 19, 2014 in Dusseldorf, Germany, that it has initiated challenges to four ResMed patents before the EPO and the German Federal Patent Court as well as the German Patent and Trade Mark Office. The ResMed patents being challenged include those ResMed asserted against Apex in Germany in November 2013. The actions started in Europe are subsequent to Apex's assault launched in August 2013 in the United States on several ResMed patents, which ResMed relied upon to sue competitors such as Apex and other manufacturers. Apex requested the U.S. Patent and Trademark Office to reconsider and reexamine the validity of 6 U.S. patents of ResMed through the 'inter partes' review process. The cases are currently pending before USPTO.

ResMed Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2013; Provides Effective Tax Rate Guidance for the Fiscal Year 2014

ResMed Inc. reported unaudited consolidated earnings results for second quarter and six months ended December 31, 2013. For the quarter, the company’s net revenue was $384,341,000 against $376,537,000 a year ago. Income from operations was $105,020,000 against $92,070,000 a year ago. Income before income tax was $109,461,000 against $98,400,000 a year ago. Net income was $86,636,000 against $77,942,000 a year ago. Diluted earnings per share were $0.60 against $0.53 a year ago. Cash flow from operations was $84.2 million for the quarter, reflecting strong underlying earnings and working capital management. Capital expenditure for the quarter was $19.7 million, while depreciation and amortization for the December quarter totaled $18.6 million. For the six months, the company’s net revenue was $742,003,000 against $716,269,000 a year ago. Income from operations was $201,903,000 against $172,558,000 a year ago. Income before income tax was $211,530,000 against $189,301,000 a year ago. Net income was $167,566,000 against $149,207,000 a year ago. Diluted earnings per share were $1.15 against $1.02 a year ago. The company disappointed with the US numbers, the two key issues, as it have previously noted, are market restructuring due to competitive bidding and increased competitor activity. The company currently estimates effective tax rate for fiscal year 2014 will also be in the vicinity of 21%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMD:US $47.44 USD +0.95

RMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $117.94 USD -0.30
MEDNAX Inc $60.45 USD +0.01
Mettler-Toledo International Inc $233.50 USD +4.65
Teleflex Inc $101.84 USD -0.34
Cooper Cos Inc/The $128.66 USD -0.52
View Industry Companies
 

Industry Analysis

RMD

Industry Average

Valuation RMD Industry Range
Price/Earnings 21.3x
Price/Sales 4.4x
Price/Book 4.1x
Price/Cash Flow 20.0x
TEV/Sales 3.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.